Your browser doesn't support javascript.
loading
Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
Koschorke, Ada; Faraci, Simona; Giani, Debora; Chiodoni, Claudia; Iorio, Egidio; Canese, Rossella; Colombo, Mario P; Lamolinara, Alessia; Iezzi, Manuela; Ladomery, Michael; Vernieri, Claudio; de Braud, Filippo; Di Nicola, Massimo; Tagliabue, Elda; Castagnoli, Lorenzo; Pupa, Serenella M.
Afiliación
  • Koschorke A; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Faraci S; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Giani D; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Chiodoni C; Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Iorio E; Core Facilities, NMR and MRI Unit, Istituto Superiore di Sanità, Rome, Italy.
  • Canese R; Core Facilities, NMR and MRI Unit, Istituto Superiore di Sanità, Rome, Italy.
  • Colombo MP; Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Lamolinara A; Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. D'Annunzio University, Chieti-Pescara, Italy.
  • Iezzi M; Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. D'Annunzio University, Chieti-Pescara, Italy.
  • Ladomery M; Faculty of Health and Applied Sciences, University of the West of England, Coldharbour Lane, Frenchay, Bristol, BS16 1QY, UK.
  • Vernieri C; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • de Braud F; IFOM, FIRC Institute of Molecular Oncology, Università degli Studi di Milano, Milan, Italy.
  • Di Nicola M; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Tagliabue E; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.
  • Castagnoli L; Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Pupa SM; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Cell Oncol (Dordr) ; 42(6): 815-828, 2019 Dec.
Article en En | MEDLINE | ID: mdl-31376137
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Células Madre Neoplásicas / Neoplasias de la Mama / Isotiocianatos / Receptor ErbB-2 Límite: Animals / Female / Humans Idioma: En Revista: Cell Oncol (Dordr) Año: 2019 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Células Madre Neoplásicas / Neoplasias de la Mama / Isotiocianatos / Receptor ErbB-2 Límite: Animals / Female / Humans Idioma: En Revista: Cell Oncol (Dordr) Año: 2019 Tipo del documento: Article País de afiliación: Italia